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Abstract
Vascular endothelial growth factor (VEGF) and its re-
ceptors (FLT-1 and KDR) are overexpressed by human
bladder cancer cells and tumor endothelial cells, re-
spectively. Strategies that target VEGF receptors hold
promise as antiangiogenic therapeutic approaches to
bladder cancer. A fusion protein of VEGF121 and the
plant toxin gelonin (rGel) was constructed, expressed
in bacteria, and purified to homogeneity. Cytotoxicity
experiments of VEGF121/rGel on the highly metastatic
253J B-V human bladder cancer cell line demonstrated
that the VEGF121/rGel does not specifically target these
cells, whereasWestern blot analysis showed no detect-
able expression of KDR. Treatment with VEGF121/rGel
against orthotopically implanted 253J B-V xenografts
in nude mice resulted in a significant suppression of
bladder tumor growth (f60% inhibition; P < .05) com-
pared to controls. Immunohistochemistry studies of
orthotopic 253J B-V tumors demonstrated that KDR is
highly overexpressed in tumor vasculature. Immuno-
fluorescence staining with antibodies to CD-31 (blood
vessel endothelium) and rGel demonstrated a dramatic
colocalization of the construct on tumor neovascu-
lature. Treated tumors also displayed an increase in
terminal deoxynucleotidyl transferase–mediateddUTP-
biotin end labeling staining compared to controls.
Thus, VEGF121/rGel inhibits the growth of human blad-
der cancer by cytotoxic effects directed against the
tumor vascular supply and has significant potential
as a novel antiangiogenic therapeutic against human
bladder cancer.
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Introduction
Transitional cell carcinoma (TCC) of the bladder is the fifth
most common solid malignancy in the United States [1].
Over 63,000 new cases and over 13,000 deaths of this
cancer are estimated for the year 2005 [2]. TCC is clas-
sified histopathologically into three types: superficial (papillary
tumors), confined to the bladder wall (pT1 and pTa tumors),
and invasive (stages T2–T4) [3]. Approximately 30% of pa-
tients with papillary tumors will progress to invasive TCC, where
radical cystectomy is the standard therapy [1]. Unfortunately,
this disease recurs in up to 50% of these patients despite
surgery and is potentially lethal. Half of patients with muscle-
invasive bladder cancer will develop metastatic disease [4].
The critical role of angiogenesis in tumor growth and metas-
tasis has prompted major efforts to develop antiangiogenic
therapies. Neovascularization is a normal, robust process that
is controlled by numerous growth factors, including basic fibro-
blast growth factor, interleukin-8, hypoxia-inducible factors (1
and 2), and vascular endothelial growth factor A (VEGF-A) [5,6].
In addition, neovascularization appears to be an essential step
to enable neoplastic growth and metastatic spread [7,8]. Ani-
mal models [9–13] as well as clinical studies [14–18] have
identified elevated levels of these cytokines and growth factors
during tumor progression and metastatic spread. In addition,
receptors for many of these cytokines are overexpressed on
the luminal surface of tumor vasculature and provide an op-
portunity for therapeutic targeting without the need to invade
the tumor parenchyma.
VEGF-A is a predominant factor mediating angiogenesis
and has been well-characterized for its pivotal involvement in
tumor development and metastases [19–22]. The angiogenic
actions of VEGF-A are primarily mediated through two closely
related receptor tyrosine kinase domain receptors designated
VEGFR-1 (Flt-1/FLT-1) andVEGFR-2 (Flk-1/KDR). These recep-
tors are overexpressed in the endothelium of tumor vasculature
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[23–25] and are almost undetectable in the vascular endo-
thelium of adjacent normal tissues. Therefore, they appear
to be excellent targets for the development of therapeutic
agents that inhibit tumor growth and metastatic spread
through inhibition of tumor neovascularization. Recent studies
have identified these receptors on breast [26], pancreatic
[27,28], and leukemic human tumor cells [29,30].
We have previously described a novel fusion construct
composed of VEGF121 and recombinant toxin gelonin (rGel),
which is highly cytotoxic at nanomolar concentrations to both
log phase and confluent endothelial cells that overexpress
the KDR receptor and is not specifically cytotoxic to cells that
overexpress the FLT-1 receptor [31]. rGel is a single-chain
n-glycosidase that is similar in its action to ricin A chain [32],
and immunotoxins and fusion constructs containing rGel
have been shown to specifically kill tumor cells in vitro and
in vivo [31–35]. In currently ongoing clinical studies, rGel
does not appear to generate vascular leak syndrome, which
limits the use of other toxins in its class [36]. The purpose of
the current study is to evaluate the biologic activity of the
vascular-targeting agent VEGF121/rGel on the growth of
a highly metastatic human bladder carcinoma 253J B-V in
an orthotopic model in nude mice. Our results show that
VEGF121/rGel significantly inhibits tumor growth and sug-
gests a potential clinical application of this vascular-targeting
agent in the treatment of invasive bladder carcinoma.
Materials and Methods
Cell Lines
Porcine aortic endothelial (PAE) cells transfected with
the human KDR receptor (PAE/KDR) were a generous gift
from Dr. J. Waltenberger and developed as described [37].
The highly tumorigenic and highly metastatic 253J B-V human
TCC cell line [38] was maintained as a monolayer culture in
MEMmedium (Life Technologies, Inc., Gaithersburg, MD) sup-
plemented with 10% fetal bovine serum, 2 mM L-glutamine,
sodium pyruvate, nonessential amino acids, 100 U/ml penicil-
lin, 100 mg/ml streptomycin, and vitamins (CMEM). The 253J
B-V cells were harvested by a 1-minute treatment with 0.025%
trypsin–0.01% EDTA solution. The culture flask was tapped
to detach the cells. The cells were washed in CMEM and re-
suspended in Hanks balanced salt solution (HBSS) in prepa-
ration for implantation into the mice.
Animals
Male athymic BALB/c nude mice were obtained from the
Animal Production Area of the National Cancer Institute,
Frederick Cancer Research Facility (Frederick, MD). The
mice were maintained in a laminar air flow cabinet under
specific pathogen-free conditions and used at 8 to 12 weeks
of age. All facilities were approved by the American Asso-
ciation for Accreditation of Laboratory Animal Care in accor-
dance with the current regulations and standards of the
United States Department of Agriculture, the Department
of Health and Human Services, and the National Institutes
of Health.
Expression and Purification of VEGF121/rGel
The construction, expression, and purification of VEGF121/
rGel have been previously described [31]. The fusion toxin
was stored in sterile phosphate-buffered saline (PBS)
at 20jC.
In Vitro Cytotoxicity Assay
The cytotoxicity assay of VEGF121/rGel and rGel against
log-phase PAE/KDR cells was performed as described pre-
viously [31], whereas that of VEGF121/rGel and rGel against
log-phase 253J B-V cells was performed as follows. Log-
phase cells (5  103) were plated in 96-well flat-bottom tis-
sue culture plates and allowed to attach overnight. On the
following day, the cells were replenished with medium sup-
plemented with 2% serum and treated with various concen-
trations of VEGF121/rGel or rGel in triplicate. After incubation
for 72 hours, the cells were treated with 50 ml of 1% MTT so-
lution and incubated for 2 hours at 37jC. The MTT solution
was removed and 100 ml of 10% DMSO was added to each
well. Absorbance was read at 570 nm on a PowerwaveX 340
Microplate Scanning Spectrophotometer (Bio-Tek Instru-
ments, Inc., Winooski, VT) using KC4 software.
Coculture of Endothelial Cells and 253J B-V Tumor Cells
253J B-V cells in log phase were plated into six-well
plates (4  103 cells/well) and allowed to attach overnight.
Sterile plastic inserts (0.4 mm) containing log-phase PAE/
KDR cells (2 103 cells/well) were placed above the bladder
cancer cells to permit a free passage of macromolecules be-
tween the two chambers. Bladder cancer cells without inserts
were grown as controls. Cells were treated with various con-
centrations of VEGF121/rGel (4–500 nM) in triplicate. After
incubation for 72 hours, the remaining adherent cells were
stained with crystal violet (0.5% in 20% methanol) and solu-
bilized with Sorenson’s buffer (0.1 M sodium citrate, pH 4.2, in
50% ethanol). Absorbance was measured at 630 nm.
Western Blot Analysis
PAE/KDR and 253J B-V cells were cultured in 10-cm
dishes with their respective media. Cells were treated with an
IC50 dose of VEGF121/rGel for 24 hours. Control cells were
treated with saline or VEGF (R&D Systems, Minneapolis,
MN). Whole cell lysates of the treated and untreated PAE/
KDR and 253J B-V cells were obtained by lysing cells in cell
lysis buffer (50 mM Tris, pH 8.0, 0.1 mM EDTA, 1 mM DTT,
12.5 mMMgCl2, 0.1 M KCl, and 20% glycerol) supplemented
with protease inhibitors [leupeptin (0.5%), aprotinin (0.5%),
and PMSF (0.1%)]. Protein samples were separated by SDS-
PAGE under reducing conditions and transferred to a nitro-
cellulose membrane. The membrane was blocked with 5%
bovine serum albumin, and the samples were analyzed for
unphosphorylated (preactivated) KDR with mouse anti–Flk-1
monoclonal antibody (Transduction Laboratories, Lexington,
KY) and for p-KDR using an antiphosphotyrosine antibody
(Santa Cruz Biotechnology, Santa Cruz, CA). Appropriate
secondary antibodies were used at 1:5000 dilution for 1 hour
and detected using an ECL detection kit (Amersham Bio-
sciences, Buckinghamshire, England, UK).
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Isolation of RNA and RT-PCR Analysis
Isolation of RNA and RT-PCR analysis was performed as
previously described [39]. Briefly, total RNA was extracted
using the RNeasy mini-kit (Qiagen, Valencia, CA), and its
integrity was verified by electrophoresis on a denaturing
formaldehyde agarose gel. RT-PCR analysis was performed
by first subjecting the isolated RNA to first-strand cDNA
synthesis, as described by the manufacturer of the Super-
script First Strand synthesis system (Invitrogen, Carlsbad,
CA). RT-PCR was performed using a Minicycler PCR ma-
chine (MJ Research, Inc., San Francisco, CA).
Orthotopic Implantation of Tumor Cells
A maximum tolerated dose of 40 mg/kg for VEGF121/rGel
delivered intravenously under the conditions described below
was established. For treatment purposes, 50% of the MTD
was used. Each mouse was anesthetized with sodium pen-
tobarbital (25 mg/kg, i.p.) and placed in the supine position.
A lower midline incision was performed, and the bladder
was exposed. The 253J B-V cells (3.5  105 cells in 50 ml of
HBSS) were implanted into the wall of the bladder in the area
of the bladder dome using 30-gauge needles on disposable
1-ml syringes. A successful implantation was indicated by a
bleb in the bladder wall serosa. The abdominal wound was
closed with metal wound clips on the first layer (Autoclips;
Clay Adams, Parsippany, NJ). Thirty mice were randomized
to three treatment groups. Treatment began on the third
day after tumor injection into the bladder. The animals were
treated with the following protocol: group 1—200 ml of saline
every other day for 10 days (five treatments); group 2—29 mg
of recombinant rGel in 200 ml of saline every other day for
10 days (five treatments); and group 3—80 mg of VEGF121/
rGel in 200 ml of saline every other day for 10 days (five treat-
ments). All treatment injections were delivered intravenously.
Twenty-one days after tumor injection, the animals were sac-
rificed, and the bladders were harvested, weighed, and pro-
cessed. For colocalization studies, a single dose of VEGF121/
rGel (80 mg) or rGel (29 mg) was administered, and animals
were sacrificed 4 hours later.
Histologic and Immunohistochemical Analysis
For histologic studies, 5-mm-thick sections were pre-
pared and stained with hematoxylin and eosin. For immuno-
histochemical analysis, frozen tissue sections (8 mm thick)
were fixed with cold acetone. Tissue sections (5 mm thick) of
formalin-fixed paraffin-embedded specimens were deparaf-
finized in xylene, rehydrated in graded alcohols, and trans-
ferred to PBS. The slides were rinsed twice with PBS, and
antigen retrieval was performed with pepsin for 12 minutes;
endogenous peroxidase was blocked by the use of 3% hy-
drogen peroxide in PBS for 12 minutes. The samples were
washed three times with PBS and incubated for 20 minutes
at room temperature with a protein-blocking solution of
PBS (pH 7.5) containing 5% normal horse serum and 1%
normal goat serum. Excess blocking solution was drained,
and the samples were incubated for 18 hours at 4jC with a
1:100 dilution of rat monoclonal anti–CD-31 antibody (Phar-
Mingen, San Diego, CA) or a 1:100 dilution of mouse anti–
Flk-1 monoclonal antibody. The samples were then rinsed
four times with PBS and incubated for 1 hour at room tem-
perature with the secondary antibody. The slides were rinsed
with PBS and incubated for 5 minutes with diaminobenzidine
(Research Genetics, Huntsville, AL). The sections were then
washed three times with PBS, counterstained with Gill’s
hematoxylin (Biogenex Laboratories, San Ramon, CA), and
washed three times with PBS. The slides were mounted with
Universal Mount mounting medium (Research Genetics).
Immunofluorescence
Frozen tissue sections (8 mm thick) were fixed with cold
acetone. The samples were washed three times with PBS
and incubated for 20 minutes at room temperature with a
protein-blocking solution containing PBS (pH 7.5), 5% nor-
mal horse serum, and 1% normal goat serum. Excess block-
ing solution was drained, and the samples were incubated
for 18 hours at 4jC with rat anti–CD-31 monoclonal anti-
body (1:400), rabbit anti-rGel polyclonal antibody (1:400),
and/or rabbit anti –Flk-1/KDR polyclonal antibody C20
(1:100). The samples were then rinsed four times with PBS
and incubated for 1 hour at room temperature with goat
antimouse FITC-conjugated secondary antibody (1:80), goat
antirabbit TRITC-conjugated secondary antibody (1:80), or
rabbit Cy5 secondary antibody (1:400). The sections were
then washed twice with PBS. The slides were mounted
and viewed.
Immunofluorescent Terminal Deoxynucleotidyl Transferase–
Mediated dUTP-Biotin End Labeling (TUNEL) Analysis
Paraffin-embedded tissue sections were sectioned (6 mm)
and deparaffinized in xylene, rehydrated in alcohol, and trans-
ferred to PBS. TUNEL was performed using a commercial
kit (Promega Corp., Madison, WI) according to the manu-
facturer’s instructions. Briefly, samples were fixed with 4%
paraformaldehyde (methanol-free) for 10 minutes at room
temperature, washed with PBS, and then permeabilized
by incubating with 0.2% Triton X-100 in PBS (vol/vol) for
15 minutes. The samples were incubated with equilibration
buffer (from the kit). A reaction buffer containing equilibration
buffer (45 ml), nucleotide mix (5 ml), and terminal deoxy-
nucleotidyl transferase (1 ml) was added to the sections and
incubated in a humidified chamber for 1 hour at 37jC, pro-
tected from light. The reaction was terminated by immersing
the samples in 2 SSC (30 mM NaCl, 3 mM sodium citrate,
pH 7.2) for 15 minutes, followed by three washes to remove
unincorporated fluorescein dUTP. Background fluores-
cence was determined by processing slides in the absence
of terminal deoxynucleotidyl transferase (negative control).
Nuclei were stained with propidium iodide (1 mg/ml) for 10min-
utes. Prolong (Molecular Probes, Eugene, OR) was used
to mount coverslips. Immunofluorescence microscopy was
performed using a Zeiss Plan-Neofluar lens on an epifluo-
rescence microscope equipped with narrow bandpass ex-
citation filters mounted in a filter wheel (Ludl Electronic
Products, Hawthorne, NY) to individually select for green
and red fluorescence. Images were captured using a cooled
CCD camera (Photometrics, Tucson, AZ). DNA fragmentation
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was detected by localized green fluorescence within the
nuclei of apoptotic cells.
Laser scanning cytometry (LSC)–mediated quantitative
analysis was used to determine the number of TUNEL-
positive cells in each tissue section, as previously described
[40]. Negative control slides were used to set the gates
on the scattergram, and each bladder tumor section was
scanned by LSC to determine the percentage of apoptotic
cells in 1  104 total cells per tumor.
Results
Cytotoxicity of VEGF121/rGel and rGel on 253J B-V Cells
Because VEGF121 binds only to KDR and FLT-1, we first
examined RNA levels of these two receptors in 253J B-V
cells. Total RNA was harvested from log-phase cells, ana-
lyzed for integrity, and subjected to RT-PCR with primers
for KDR, FLT-1, and GAPDH (control). PAE/KDR and PAE/
FLT-1 cells were used as positive controls. 253J B-V cells did
not express detectable levels of KDR or FLT-1 RNA as de-
termined by RT-PCR (Figure 1A). The direct cytotoxic effect
of VEGF121/rGel and rGel on 253J B-V cells was initially
evaluated in vitro and compared to their cytotoxic effect on
PAE/KDR cells. As previously described [31], treatment of log-
phase cells with VEGF121/rGel for 72 hours showed the
greatest cytotoxic effect against PAE/KDR cells, with an
IC50 of 1 nM (Figure 1B). In contrast, the IC50 of the untargeted
rGel on these cells was approximately 100 nM, similar to the
IC50 of VEGF121/rGel on 253J B-V cells. However, 253J B-V
cells were approximately seven-fold more sensitive to the
cytotoxic effects of the VEGF121/rGel construct compared to
that of the untargeted rGel toxin (100 vs 700 nM, respectively).
These values are similar to those for other tumor cells [31].
These values indicate some—but relatively poor—targeting
of VEGF121/rGel to 253J B-V cells and that VEGF121/rGel is
far more potent toward endothelial cells that overexpress
the KDR receptor than to 253J B-V cells in vitro.
Determination of KDR Expression on 253J B-V Cells
by Western Blot Analysis
Previous studies in our laboratory show that the pres-
ence of the KDR receptor is critical to the development of
VEGF121/rGel–mediated cytotoxicity. Therefore, we as-
sessed the presence of KDR and p-KDR in PAE/KDR and
253J B-V cells. Cells were treated with VEGF121/rGel or
VEGF165 for 24 hours and then processed as described. As
shown in Figure 2, the KDR receptor was detected in PAE/
KDR—but not 253J B-V—lysates, suggesting that 253J B-V
cells do not express detectable amounts of KDR, in support
of the cytotoxicity data obtained. PAE/KDR cells treated with
VEGF121/rGel resulted in phosphorylation of the KDR recep-
tor. However, p-KDR was not detected in 253J B-V lysates
after treatment with either VEGF165 or with VEGF121/rGel.
Evaluation of Flk-1/KDR Expression in 253J B-V
Orthotopic Bladder Tumors In Vivo
This highly aggressive tumor model was assessed for
its vascularity and the expression of Flk-1 on the vascular
endothelium. As shown in Figure 3, numerous blood vessels
were observed in 253J B-V tumors. In addition, all vessels
demonstrated a colocalization of Flk-1 with CD-31, indicating
that Flk-1 receptors are overexpressed only on vascular
Figure 1. 253J B-V cells are not targeted by VEGF121/rGel. (A) RT-PCR
analysis demonstrating that 253J B-V cells do not express detectable levels
of the VEGF121 receptors KDR and FLT-1. Endothelial cells transfected with
KDR (PAE/KDR) and FLT-1 (PAE/FLT-1) are used as positive controls. (B)
In vitro cytotoxicity of VEGF121/rGel on 253J B-V cells. Log-phase cells were
plated in 96-well plates and incubated with serial dilutions of VEGF121/rGel
and rGel for 72 hours, as described in ‘‘Materials and Methods.’’ The cyto-
toxicity experiment was performed in triplicate, and data points are repre-
sented as the mean. VEGF121/rGel is far more toxic than rGel on PAE/KDR
cells (IC50 of 1 vs 100 nM). In contrast, the cytotoxic effects of both agents are
substantially reduced toward 253J B-V cells (IC50 of 100 nM with VEGF121/
rGel vs 700 nM with rGel), demonstrating a less specific cytotoxicity of the
fusion construct compared to free toxin on these cells.
Figure 2. KDR is not detectable on 253J B-V cells. Whole cell lysates were
prepared and used in Western blot analysis as described in ‘‘Materials and
Methods.’’ A 235-kDa protein corresponding to KDR was seen in PAE/KDR
lysates. No KDR was detected in 253J B-V lysates. Phosphorylated KDR was
detected only in PAE/KDR that had been treated with VEGF121/rGel. IgG is
used as a control for loading.
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endothelial cells and are not detectable on tumor cells using
this method.
Treatment of Orthotopic 253J B-V Tumors
with VEGF121/rGel
The therapeutic and antiangiogenic effect of the fusion
protein VEGF121/rGel was evaluated against human blad-
der cancer xenografts growing in athymic nude mice. The
mice were treated every other day with a total of 20 mg/kg
VEGF121/rGel, rGel, or saline. The mice were necropsied
21 days after tumor implantation, and bladder tumors were
harvested, weighed, and processed. No difference was ob-
served in tumor weight from mice treated with saline or rGel
(Figure 4; P < .05). In contrast, tumors frommice treated with
VEGF121/rGel weighed about 40% that of the control (P < .05).
To further understand the mechanisms leading to cyto-
toxic effects against the tumor in vivo, we performed co-
culture experiments of 253J B-V cells with PAE/KDR cells,
simulating the in vivo setting of tumor cells and endothelial
cells. We used VEGF121/rGel dose levels that are 80% to
100% cytotoxic to PAE/KDR cells but are mildly cytotoxic to
253J B-V cells. We observed no difference in VEGF121/
rGel–mediated cytotoxicity between 253J B-V cells grown
alone or in coculture (data not shown). The results suggest
that VEGF121/rGel–mediated inhibition of the growth of
human bladder cancer in vivo is not due to the effect per se
of factors released by damaged endothelial cells. Rather, the
results support our hypothesis that tumor cell death is a sec-
ondary effect due to specific damage to tumor vasculature.
Immunofluorescence and Localization of VEGF121/rGel
in Tumors
Bladder tumors from treated mice were processed for his-
tology and immunohistochemical analysis. Tissues for colocal-
ization experiments were harvested 4 hours after VEGF121/
rGel or rGel treatment. Immunofluorescence of tumor tissue
sections with anti–CD-31 and anti-rGel antibodies showed
a dramatic colocalization of VEGF121/rGel with CD-31 on the
tumor neovasculature (Figure 5), indicating that VEGF121/
rGel targets the tumor endothelium. In some instances,
VEGF121/rGel did not colocalize with CD-31. VEGF121/rGel
was not detected in other tissues (data not shown). Immuno-
staining with the anti-rGel antibody of tumors of animals
treated with rGel was negative, indicating the specificity of
VEGF121 as a targeting moiety for the tumor vasculature.
Immunofluorescence and Localization of Flk-1/KDR
in Tumors
Bladder tumors from treated and control mice were har-
vested at the end of the study and processed for histology
and immunohistochemical analysis. Immunofluorescence
with the anti–CD-31 antibody of tumor tissue sections of
mice treated with VEGF121/rGel revealed a vasculature that
is less dispersed and more clustered compared to saline-
treated mice, with far fewer vascular networks. Colocaliza-
tion staining with anti –Flk-1/KDR antibody surprisingly
showed an increase in the number of Flk-1/KDR receptors
in tumors of mice treated with VEGF121/rGel versus rGel
(Figure 6). The average increase in Flk-1/KDR levels was
34.4% after VEGF121/rGel treatment (P < .02). Almost all the
Flk-1/KDR stainings colocalized with CD-31.
TUNEL Analysis of Bladder Tumors
To study the in vivo effect on tumor cells as a result
of VEGF121/rGel cytotoxicity on endothelial cells, bladder
tumors from mice treated with VEGF121/rGel, rGel, and sa-
line were stained for apoptotic effects. Both necrotic as
well as non-necrotic regions were examined. As shown in
Figure 7, tumors treated with either saline or rGel showed
virtually no apoptotic regions. In comparison, treatment with
VEGF121/rGel resulted in a slight increase in apoptosis. The
results of LSC quantification are shown in Table 1. VEGF121/
rGel–treated tumors showed a significantly higher TUNEL
staining than rGel- or saline-treated tumor-bearing mice.
Discussion
Although bladder cancer responds to traditional chemother-
apeutic approaches, resistance and relapse occur even in
Figure 3. Immunohistochemistry of 253J B-V bladder tumor tissue. Immuno-
histochemistry performed with anti –CD-31 and anti –Flk-1 antibodies demon-
strates a colocalization of Flk-1/KDR with CD-31. Flk-1/KDRwas not expressed
by 253J B-V tumor cells, but was found only on the tumor vasculature.
Figure 4. Effects of VEGF121/rGel treatment on the in vivo growth of
orthotopic 253J B-V cells. Tumor-bearing mice were treated intravenously
with saline, rGel, or VEGF121/rGel. Mice were necropsied 21 days after tumor
implantation, and bladder tumors were harvested. Treatment with VEGF121/
rGel results in a significant suppression of bladder tumor growth (roughly
60%) compared to controls (P < .05).
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those patients who attain a complete response, and patients
withmetastatic disease generally face a poor prognosis. Blad-
der primary tumors and metastatic sites appear to be highly
vascular and depend on numerous soluble factors and their
receptors to mediate the growth and development of the
intratumoral vascular tree. Targeting angiogenic mechanisms
within these tumors potentially offers another therapeutic
modality that may not be susceptible to resistance. However,
this is a difficult endeavor because there are so many factors
capable of controlling angiogenesis.
We have previously reported that VEGF121/rGel is cyto-
toxic to endothelial cells overexpressing the KDR receptor
rather than the FLT-1 receptor [31], and that endothelial
cells expressing the KDR receptor below a threshold
number (approximately 2  103 receptors per cell) are sev-
eral hundred-fold more resistant to VEGF121/rGel than are
cells overexpressing KDR (1–3  105 receptors per cell)
[31]. Although Flt-1 binds VEGF with a 50-fold higher affinity
than KDR [41], most of the VEGF angiogenic properties
(mitogenicity, chemotaxis, and induction of morphologic
changes) are mediated by interactions with KDR [37]. The
IC50 of VEGF121/rGel for PAE/KDR, an endothelial cell line
that overexpresses KDR (mimicking proliferating endothelial
cells during angiogenesis), is 1 nM. VEGF121/rGel cyto-
toxicity toward other tumor cell lines in vitro is much higher,
and in vivo efficacy studies suggest that the activity of
VEGF121/rGel at low doses is due to its cytotoxicity toward
endothelial cells and not the tumor. To test the cytotoxicity
of VEGF121/rGel toward the bladder cell line 253J B-V, we
performed an in vitro cytotoxicity assay and found that the
IC50 of VEGF121/rGel for this highly metastatic cell line was
100 nM, comparable to that of VEGF121/rGel with other
tumor cell lines and much higher than the IC50 toward pro-
liferating endothelial cells. The cytotoxicity of the free toxin
to PAE/KDR cells is different compared to the cytotoxicity
to 253J B-V cells. As observed previously, it is possible
that the rate or route of entry of rGel is different based on
the rate of cell division, which can vary from one cell type to
Figure 5. Immunofluorescence of tumor tissue sections of mice treated with rGel or VEGF121/rGel. Samples were processed as described in ‘‘Materials and
Methods.’’ Panel A: CD-31 (green) is seen in tissue sections of mice treated with both VEGF121/rGel and rGel. Panel B: However, the presence of rGel (red) is
only seen in tumor tissues of mice treated with VEGF121/rGel. Panel C: Overlay of anti –CD-31 and anti-rGel antibody fluorescence shows a colocalization of
rGel and CD-31, indicating that VEGF121/rGel targets the tumor neovasculature. No such colocalization of rGel and CD-31 is seen in tumors of animals treated
only with rGel.
Figure 6. Effect of VEGF121/rGel treatment on Flk-1/KDR levels in orthotopic
bladder tumors. CD-31 (red) is seen in tissue sections of mice treated with
both VEGF121/rGel and rGel (control). VEGF121/rGel treatment results in a
reduced network of tumor vessels. Flk-1/KDR (green) levels appear to be
localized to the tumor vasculature and show an average increase of 34.4%
(P < .02) following VEGF121/rGel treatment.
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another. Although the higher cytotoxicity of VEGF121/rGel
than rGel toward 253J B-V cells suggests the presence of a
VEGF121 receptor, the receptor levels are fairly low, as sup-
ported by RT-PCR, Western and immunohistochemistry
data point to the importance of high receptor levels in
VEGF121/rGel–mediated cytotoxicity and destruction of the
tumor vasculature. Indeed, immunostaining of orthotopic
253J B-V tumors localized p-KDR to tumor-associated en-
dothelial cells [42]. To date, there are only two reports of KDR
expression on TCCs [43,44].
Our results show an average increase of 34.4% in Flk-1/
KDR levels in VEGF121/rGel– treated mice compared to
controls (P < .02), the majority of which appear to be on
the vasculature. Note that VEGF121/rGel treatment results in
a vasculature that is less dispersed and more clustered,
subjecting tumor cells that are distant from the vasculature
to hypoxic stress. The increase in total Flk-1/KDR levels is
similar to that observed in the treatment of 253J B-V tumors
with DC101, an anti–Flk-1 antibody [42]. Previous results
suggest that induction of Flk-1 occurs preferentially within
regions of relative hypoxia (i.e., in the tumor core) [42]. In
addition, VEGF plays a role in the paracrine stimulation
of angiogenesis [45,46] but may also act through an auto-
regulatory pathway that is activated when VEGF signal
transduction is interrupted [47]. Growth-regulatory pathways
are often controlled by feedback loops that reduce the ex-
pression of pathway components when signal transduction
is active and increase levels when signaling is inactive. In
the orthotopic 253J-BV tumor model, upregulation of Flk-1/
KDR could serve to rapidly reestablish the vascular network
once therapy is terminated.
Treatment of the orthotopic 253J B-Vmodel with VEGF121/
rGel resulted in a 60% inhibition of tumor growth compared
to rGel-treatedmice. This compares favorably to therapy with
a blocking antibody against murine VEGFR-2 in the same
tumor model [42]. Although bladders in this experiment were
harvested, weighed, and processed 21 days after tumor
injection, it is possible that a higher rate on inhibition can be
observed at different time points after tumor injection, de-
pending on the expression of VEGFR-2 in the tumor vascular
endothelium. Further studies are warranted.
Molecular engineering has enabled the synthesis of novel
chimeric molecules that have therapeutic potential. Chime-
ric fusion constructs targeting the IL-2 receptor [48,49], EGF
receptor [50], and other growth factor cytokine receptors
have been described. Studies by Olson et al. [51] and
Ramakrishnan et al. [52] showed that a chemical conjugate
of VEGF and truncated diphtheria toxin (DT) displayed an
impressive cytotoxic activity on cell lines expressing recep-
tors for VEGF. Further studies with VEGF–DT fusion con-
structs demonstrated selective toxicity to Kaposi’s sarcoma
cells and dividing endothelial cells in vitro and in vivo [53].
The association of bladder cancer progression with pro-
angiogenic agents has been suggested for at least 20 years,
with the demonstration that urine from cancer patients in-
duces neovascularization in a rat cornea model [54]. In ad-
dition, endothelial cells in bladder tumors overexpress the
mRNA for Flt-1 and KDR [55]. Studies of non–small cell lung
cancer and melanoma have since confirmed a link between
neovascularization, microvessel density, and survival or prog-
nosis; however, this remains somewhat controversial [56–58].
Previous studies using agents such as interferon have dem-
onstrated an ability to inhibit tumor growth in this bladder tumor
model primarily through an antiangiogenic mechanism [1,59].
Because the VEGF121/rGel fusion toxin is primarily cytotoxic
to vascular endothelial cells rather than directly cytotoxic to
bladder tumor cells, the tumor growth-inhibitory effects noted
in this model are due solely to effects on tumor vasculature.
The mechanism of action of VEGF121/rGel on endothelial
cells in vitro appears to be necrotic (data not shown), and the
proapoptotic effects observed on bladder tumor cells appear
to result from hypoxic stress and pH changes secondary to
the vascular disruption effects of the construct because this
agent does not appear to directly cause apoptotic effects in
intoxicated cells.
The development of targeted therapeutic approaches for
bladder cancer generally includes agents directed against
the tumor cells themselves [60]. Thiesen et al. [61] initially
reported a promising approach using antibodies recognizing
Figure 7. TUNEL analysis of orthotopic bladder tumors. Tumors treated with VEGF121/rGel show a much higher TUNEL staining compared to controls. Negative
control denotes cells analyzed for TUNEL without the addition of terminal deoxynucleotidyl transferase. Control is a bladder tumor treated with rGel. LSC-mediated
quantitative analysis is shown in Table 1.
Table 1. LSC-Mediated Analysis of TUNEL Staining of Orthotopically Placed
253J B-V Bladder Tumors of Mice Treated with rGel or VEGF121/rGel.
Treatment % TUNEL-Positive
rGel 2.73 ± 0.72 (n = 3)*
VEGF121/rGel 6.3 ± 1.67 (n = 3)*
*P = .027.
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transitional bladder carcinoma cells linked to ricin A or B
chains. More recently, Zang et al. [62] reported on the clinical
efficacy of a BD1-RT immunotoxin administered after resec-
tion through the intravesicular route in patients with bladder
cancer. The comparison to the control group treated with
mitomycin C demonstrated no statistically significance dif-
ferences between the groups in terms of recurrence rates;
however, the side effect rates were reportedly lower for the
immunotoxin group.
Intravesicular therapy is an attractive option for bladder
cancer because relatively high doses of therapeutic agents
can be delivered by establishing a direct contact with the
bladder tumor, thereby providing minimal systemic side ef-
fects. However, agents targeting the tumor vasculature, such
as VEGF121/rGel, operate in the luminal side of the blood
vessels; therefore, intravesicular therapy does not appear to
be an option. However, multimodality therapy using vascular-
targeted agents delivered intravenously—in combination with
chemotherapeutic or biologic agents targeting the tumor cells
themselves or other aspects of the neovascularization pro-
cess and delivered either systemically or intravesicularly—
may have some benefits. Recent studies suggest that the use
of antiangiogenic agents may potentiate the efficacy of chemo-
therapy. This area is currently under intensive investigation [63].
In conclusion, VEGF121/rGel is a promising cytotoxic
agent that targets the neovasculature of bladder carcinoma
and is an excellent candidate for clinical trials and potential
combination therapy for the treatment of bladder cancer.
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